Biotech: Page 62
-
Elizabeth Regan/BioPharma Dive
BridgeBio looks for comeback with trial results for muscular dystrophy drug
Positive signs for the experimental treatment could help shore up investor confidence in BridgeBio after the December study failure of a drug for a rare heart condition.
By Jonathan Gardner • March 14, 2022 -
Nektar, Bristol Myers drug combination fails in late-stage melanoma trial
The trial results were the most significant setback for the companies' four-year-old partnership and will likely force Nektar to cut costs.
By Ned Pagliarulo • March 14, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna extends patent waiver for COVID vaccine, but only for lower-income countries
Health advocates say Moderna is narrowing its pledge not to enforce patents worldwide for the duration of the pandemic, while the company argues that, in higher-income countries, vaccine supply isn't a barrier to access anymore.
By Jonathan Gardner • March 8, 2022 -
Bluebird's CFO resigns as cash woes raise doubts about its future
The gene therapy developer's top financial executive, Gina Consylman, is stepping down amid concerns the company needs to raise additional cash to survive for more than a year.
By Jonathan Gardner • March 7, 2022 -
Permission granted by Biogen
Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money
Biogen confirmed that some of its U.S. employees have been informed their roles are being eliminated. The magnitude of the layoffs and which departments are most affected is unclear, however.
By Jacob Bell • March 3, 2022 -
Amid biotech downturn, Atlas raises $450M to build new drug startups
While a stock market slide has made IPOs difficult for young biotech companies, venture capital firms like Atlas are still reloading with new cash to create and invest in new drugmakers.
By Ned Pagliarulo • March 3, 2022 -
Pierre Crom via Getty Images
'We have to make a stand': Biotech leaders vow to break ties with Russia over Ukraine war
Biotech CEOs Paul Hastings and Jeremy Levin explained the goals behind a letter supported by more than 400 executives and investors that calls for drugmakers to stop working with Russian companies.
By Ben Fidler , Ned Pagliarulo • Updated March 1, 2022 -
Permission granted by Gilead Sciences
FDA rejects Gilead's closely watched HIV drug
According to Gilead, the agency has concerns about the interaction between an injectable solution of the drug, called lenacapavir, and the vials in which it's contained.
By Jacob Bell • March 1, 2022 -
Maddie Meyer via Getty Images
Moderna sued for allegedly infringing patents tied to COVID-19 vaccine
Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies.
By Ned Pagliarulo • Feb. 28, 2022 -
Biohaven stocks up on experimental drugs with new acquisition, licensing deal
Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.
By Jacob Bell • Feb. 25, 2022 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna bets on booster demand, advancing new 'bivalent' COVID-19 shot
The biotech will start trials in the U.S. and U.K. of a vaccine that targets both the original coronavirus strain and the omicron variant.
By Jonathan Gardner • Feb. 24, 2022 -
Amicus' SPAC deal unravels, leading to layoffs and cost cuts
The biotech is calling off plans to spin out its gene therapy business via a merger with a blank check company, citing unfavorable market conditions and a "challenging environment."
By Kristin Jensen • Feb. 24, 2022 -
Kodiak crashes on negative trial results for would-be Eylea competitor
Data from a Phase 3 trial showed Kodiak's experimental treatment didn't match up to Eylea in wet AMD, spurring questions from analysts about its potential.
By Kristin Jensen • Feb. 23, 2022 -
Permission granted by Spark Therapeutics
Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down
Jeffrey Marrazzo has led Spark since its founding in 2013, through the historic FDA approval of Luxturna and the company's $4.3 billion buyout by Roche.
By Ned Pagliarulo • Feb. 23, 2022 -
Maddie Meyer via Getty Images
Moderna, on the heels of pharma rivals, cleared to advance RSV vaccine
The race to launch the first preventive shot for the common respiratory illness now has four entrants in Phase 3 testing, although bigger drugmakers lead the mRNA specialist.
By Jonathan Gardner • Feb. 22, 2022 -
Permission granted by Adagio Therapeutics
Adagio pledges to press forward with COVID drug as CEO to resign
Tillman Gerngross, who founded Adagio and helped it raise $800 million on the promise of finding better antibody medicines for COVID-19, will step down amid confusion over how well its lead treatment works against omicron.
By Ned Pagliarulo • Feb. 22, 2022 -
BraunS via Getty Images
Sponsored by SGSMeso Scale Discovery (MSD): An immunoassay platform with varied applications in the biopharmaceutical industry
Learn how MSD is a one stop immunoassay platform that could be a time- and cost-effective alternative to the regularly used bio-molecule detection technologies in the laboratory.
By Riya Binil, Scientific Leader, Cell Biology • Feb. 22, 2022 -
Jonathan Gardner/BioPharma Dive
With drug approval, Agios hits first key milestone after major shakeup
The biotech, which recently narrowed its research focus to rare blood disorders, is now cleared by the FDA to start selling the first medicine for a rare form of anemia.
By Jacob Bell • Feb. 18, 2022 -
Yumanity cutting 60% of employees as it mulls possible sale
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.
By Jacob Bell • Feb. 17, 2022 -
luismmolina via Getty Images
J&J to explore RNA reprogramming with Remix research deal
The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.
By Kristin Jensen • Feb. 17, 2022 -
Permission granted by Third Harmonic
Third Harmonic, led by former Audentes CEO, launches with $155M in funding
Natalie Holles was named as head of the Atlas-backed startup last year after leaving gene therapy developer Audentes following its acquisition by Astellas.
By Ned Pagliarulo • Feb. 16, 2022 -
sololos via Getty Images
Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies
Star Therapeutics has an unusual hub-and-spoke model that it believes will make rare disease research more efficient. Its first company was unveiled Wednesday, and CEO Adam Rosenthal says another is waiting in the wings.
By Jacob Bell • Feb. 16, 2022 -
Kena Betancur via Getty Images
How the biotech downturn is already affecting drug startups
At an industry conference Monday, a group of venture investors noted changes in how long biotechs are taking to raise money, and a shifting outlook among investors who specialize in shepherding young companies to an IPO.
By Ben Fidler • Feb. 14, 2022 -
Permission granted by Mateusz Bartkowiak (QIAGEN)
Sponsored by QIAGENThe key to target and biomarker discovery
The secret's in the biological context: how to accelerate biological discovery and validation.
Feb. 14, 2022 -
libre de droit via Getty Images
ProQR eye drug comes up short in key study, surprising company and investors
The biotech's treatment did not improve vision in the Phase 2/3 trial, a significant setback that sent shares down by 75%.
By Ned Pagliarulo • Feb. 11, 2022
Previous
